Drug reimbursement up 4% y-o-y in January-November 2017

The National Health Fund (NFZ) spent PLN 10.9bn (€2.6bn) on drug reimbursement in January-November 2017, an increase of 4% compared with the corresponding period of 2016. The amount represents 88.9% of the NFZ’s most recent estimate of its drug reimbursement spending in the full year, i.e. PLN 12.3bn (€2.9bn).

Expenditures on the reimbursement of medicines, foods for particular nutritional uses and medical devices available upon prescription in the pharmacy channel amounted to PLN 7.5bn (€1.8bn) in January-November 2017, an increase of 2.4% year on year. The amount constitutes 91.3% of the full-year estimate.

Reimbursement via drug programmes totalled PLN 2.8bn (€662m) and was 10% higher than in January-November 2016. The amount represents 84.2% of a full-year estimate of PLN 3.3bn (€787m).

Expenditures on chemotherapy drugs came to nearly PLN 573m (€137m), up 5% year on year. The amount represents 84.7% of the full-year estimate (PLN 676m or €162m).

NFZ spending on drug reimbursement (PLN m), change (%, y-o-y) and its share (%) in planned 2017 budget (PLN m), January-November 2016 and 2017
 
PMR based on NFZ, 2018
Specification Jan-Nov 2016 Jan-Nov 2017 Change Planned budget for 2017 Spending in Jan-Nov 2017 as a percentage of planned budget
Medicines, foods for particular nutritional uses and medical devices available upon prescription in the pharmacy channel 7,353.78 7,530.87 2.4% 8,251.48 91.27%
Reimbursement via drug programmes 2,515.48 2,772.44 10.2% 3,294.21 84.16%
Chemotherapy drugs 546.14 572.59 4.8% 675.75 84.73%
Other 18.08 19.37 7.1% 34.74 55.76%
Total 10,433.48 10,895.28 4.4% 12,256.18 88.90%